Figure 2 Overview of risk factors for Parkinson disease dementia

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Life expectancy at birth in all countries included

Figure 1 Perivenous distribution of multiple sclerosis lesions

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Cerebrospinal fluid levels of neurofilament light chain

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Patterns of brain atrophy in Alzheimer disease

Nat. Rev. Neurol. doi: /nrneurol

Early Dementia Distinguishing AD From MCI

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 2 Grey matter atrophy in FTD

Figure 1 Allele frequency and effect size for ALS-associated genes

Figure 2 Algorithm for immunosuppressive treatment

Figure 2 Precision medicine based on a network approach

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 4 Flow chart of the MDS MSA Study Group aims

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Evolution of multiple sclerosis

Figure 1 The trajectory of cognitive ageing

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Diagnostic scheme for MSA

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 4 11C-PK11195-PET scans showing the evolution of neuroinflammation in a patient after stroke Figure 4 | 11C-PK11195-PET scans showing the evolution.

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Tau PET images in patients with Alzheimer disease

Figure 2 Title page of An Essay on the Shaking Palsy

Figure 2 Pathophysiological mechanisms in LGMD

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 5 Interaction between infarction and amyloid deposition

Figure 1 A large number of genes are potentially associated with CIPN

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Overview of the imaging biomarker roadmap

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 A case of early-onset PSD

Figure 2 Network connections of the hypothalamus

Figure 2 Aβ-PET scans obtained using different tracers

Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI

ROC curve for the TYM-MCI, ACE-R and MMSE in the separation of patients with aMCI/AD from those with SMC. ACE-R, Addenbrooke’s Cognitive Examinations;

Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;

Presentation transcript:

Figure 2 Overview of risk factors for Parkinson disease dementia Figure 2 | Overview of risk factors for Parkinson disease dementia. Three different categories of risk factors for Parkinson disease dementia (PDD) — clinical, molecular, and structural/functional imaging — are illustrated. Factors with evidence from longitudinal studies are shaded pink, and factors with evidence from cross-sectional studies are shaded grey. Interrelationships between factor categories (bidirectional arrows) and temporal relationships between cross-sectional factors and PDD (unidirectional arrows) remain unclear. MCI, mild cognitive impairment; MEG, magnetoencephalogram. Aarsland, D. et al. (2017) Cognitive decline in Parkinson disease Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.27